|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 10,195,214 and the U.S. Mifepristone–CYP3A Inhibitor Patent Landscape
US Patent 10,195,214 is directed to a specific dosing adjustment for mifepristone in endogenous Cushing’s syndrome, combined with co-administration of a “strong CYP3A inhibitor” selected from a defined list. The claims are method-of-treatment claims that hinge on (i) a patient being on an “original once-daily dose of 1200 mg or 900 mg per day,” (ii) reducing that dose to 600 mg once daily, and (iii) administering 600 mg mifepristone together with a strong CYP3A inhibitor (with multiple enumerated exemplars and dependent species claims for at least ketoconazole/itraconazole/clarithromycin).
What does US 10,195,214 claim for Cushing’s syndrome dosing with CYP3A inhibitors?
Answer: A method that requires (1) baseline mifepristone dosing at 1200 mg or 900 mg once daily, (2) reduction to 600 mg once daily, and (3) co-administration of 600 mg mifepristone with a “strong CYP3A inhibitor” chosen from a fixed list.
Claim architecture: one independent method and multiple related therapeutic embodiments
Based on the provided claim text, the patent has at least:
- Claim 1 (independent): Treating Cushing’s syndrome with dosing reduction to 600 mg once daily after the patient was taking 1200 mg or 900 mg once daily mifepristone, plus a strong CYP3A inhibitor from an enumerated list.
- Claims 2–4 (dependent): Same method as claim 1, with the CYP3A inhibitor limited to:
- Claim 2: ketoconazole
- Claim 3: itraconazole
- Claim 4: clarithromycin
- Claim 5 (independent or separate independent-style): Treating symptoms associated with elevated cortisol levels under the same dosing and CYP3A inhibitor structure.
- Claims 6–9 (dependent): Same as claim 5, with inhibitor limited to:
- Claim 6: itraconazole
- Claim 7: ketoconazole
- Claim 8: clarithromycin
- Claim 9: itraconazole (duplicate species as written)
- Claim 10 (independent): Controlling hyperglycemia secondary to hypercortisolism in endogenous Cushing’s syndrome using the same dosing reduction + CYP3A inhibitor selection.
- Claims 11–13 (dependent): Same as claim 10, with inhibitor limited to:
- Claim 11: ketoconazole
- Claim 12: itraconazole
- Claim 13: clarithromycin
The claim “core” is pharmacokinetic interaction driven
The strongest claim constraint is not the disease phrase. It is the combination of:
- Baseline mifepristone regimen: 1200 mg or 900 mg once daily.
- Adjusted regimen: 600 mg once daily.
- CYP3A inhibition: “strong CYP3A inhibitor” from a closed set:
- ketoconazole, itraconazole, nefazodone, ritonavir, nelfmavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranivir, paritaprevir, voriconazole.
This framing is typical of dose adjustment strategies intended to offset increased mifepristone exposure when CYP3A is inhibited.
Literal scope: what must be true for infringement?
For a method to fall within the claims as written, the practicing regimen must satisfy all claim elements:
- The patient must be “taking an original once-daily dose of 1200 mg or 900 mg per day of mifepristone.”
- The prescriber must “reducing” to “an adjusted once-daily dose of 600 mg mifepristone.”
- The regimen must include administering the adjusted 600 mg once daily with a strong CYP3A inhibitor from the claim’s enumerated list.
- For each claim, the intended treatment outcome must match:
- Cushing’s syndrome (claim 1),
- symptoms associated with elevated cortisol levels (claim 5),
- hyperglycemia secondary to hypercortisolism in endogenous Cushing’s syndrome (claim 10).
Therapeutic scope is broad enough to cover multiple clinical endpoints
Even though all claims share the same dosing and CYP3A inhibitor structure, the disease statements add parallel routes to enforcement:
- Primary disease claim: “Cushing’s syndrome.”
- Symptom-based claim: “symptoms associated with elevated cortisol levels.”
- Complication-based claim: “hyperglycemia secondary to hypercortisolism” in endogenous Cushing’s syndrome.
Practically, that supports enforcement across at least two common downstream clinician goals in Cushing’s patients: cortisol symptom control and metabolic complications.
Dependent claims create species-specific “hooks” for major inhibitors
Claims 2–4, 6–8, and 11–13 lock in three high-likelihood co-medications:
- ketoconazole
- itraconazole
- clarithromycin
Those are frequently used antifungals and macrolides, which increases the probability that real-world prescribing overlaps the enumerated CYP3A inhibitor set.
How should the claims be mapped to practice: step-by-step dosing + inhibitor selection?
Answer: A regimen must replicate the sequence: start at 1200/900 mg daily mifepristone, reduce to 600 mg daily, then co-administer 600 mg daily mifepristone plus one enumerated strong CYP3A inhibitor.
Element-by-element breakdown for coverage analysis
-
Baseline condition
Patient is “taking” mifepristone at 1200 mg or 900 mg once daily.
- This element is significant for infringement: it ties the claim to patients on a higher-dose maintenance/uptitration history rather than treatment-naïve patients starting at 600 mg.
-
Dose adjustment step
“Reducing the original once-daily dose to an adjusted once-daily dose of 600 mg.”
- A switch from 1200 to 600 and from 900 to 600 both fall within the literal wording.
-
Combination therapy step
Administer “the adjusted once-daily dose of 600 mg mifepristone and a strong CYP3A inhibitor.”
- The CYP3A inhibitor must be one selected from the enumerated group.
-
Outcome framing
- Claim 1: treat “Cushing’s syndrome.”
- Claim 5: treat “symptoms associated with elevated cortisol levels.”
- Claim 10: control “hyperglycemia secondary to hypercortisolism” in endogenous Cushing’s syndrome.
Practical “infringement risk” profiles
- Highest risk is when clinicians adjust down to 600 mg due to CYP3A inhibition (for example, ketoconazole or itraconazole) after the patient previously received 900/1200 mg.
- Lower risk is when patients never reached 900/1200 mg, or when the co-administered CYP3A inhibitor is not in the enumerated list, or when the dose is adjusted to a value other than 600 mg.
What “strong CYP3A inhibitor” list does US 10,195,214 include, and how does that affect design-around?
Answer: The claim uses a closed, enumerated list of strong CYP3A inhibitors; designing around requires avoiding that set or avoiding the 1200/900-to-600 dosing adjustment.
Enumerated strong CYP3A inhibitors in the claims
The list includes:
- Antifungals: ketoconazole, itraconazole, posaconazole, voriconazole
- Antivirals / protease inhibitors / boosters: ritonavir, nelfmavir, indinavir, lopinavir, saquinavir, cobicistat, tipranivir, paritaprevir
- Direct-acting antiviral: boceprevir, telaprevir
- Macrolide: clarithromycin
- Other CYP3A inhibitors: nefazodone, conivaptan, troleandomycin
Design-around implications (claim construction oriented)
- Avoid enumerated inhibitor: If a competitor co-administers a CYP3A inhibitor not in the list (and the court construction treats the list as closed), literal infringement is reduced for these claims.
- Avoid the specific dose reduction: If dosing is adjusted differently (not to 600 mg), literal infringement is avoided.
- Avoid baseline dosing condition: If the patient never “is taking” 1200 mg or 900 mg before the reduction step, literal infringement is harder.
Which therapeutic endpoints are covered: Cushing’s syndrome, cortisol symptoms, and hyperglycemia?
Answer: The patent covers three endpoint categories using the same dosing + CYP3A inhibitor structure: disease control, cortisol symptom control, and metabolic complication control.
Endpoint categories
-
Cushing’s syndrome treatment (claim 1)
Focuses on the overall syndrome.
-
Cortisol symptom treatment (claim 5)
Broadens enforcement to symptom management tied to elevated cortisol, not only “Cushing’s syndrome” as labeled diagnosis.
-
Hyperglycemia control in endogenous Cushing’s (claim 10)
Narrows to a specific complication and a specific patient population wording (“endogenous Cushing’s syndrome”), but uses the same dosing + inhibitor framework.
Why this matters for licensing and litigation
Different endpoint pleadings support different theories for induced infringement or direct method performance, depending on how evidence of clinical practice and prescribing rationale is developed. The patent gives multiple claim paths without changing the key pharmacokinetic interaction elements.
What is the expected infringement posture for ketoconazole, itraconazole, and clarithromycin?
Answer: The patent includes species-dependent claims that directly name these three widely used CYP3A inhibitors, increasing evidence availability in clinical records and reducing the argument burden around “selection” of an inhibitor.
Species-specific dependent claim coverage
- ketoconazole: claims 2, 7, 11
- itraconazole: claims 3, 6, 9, 12
- clarithromycin: claims 4, 8, 13
Evidence availability in practice
Clinical documentation typically records:
- prescribed drug names,
- dosing changes,
- adverse effect mitigation and medication interactions,
- indication notes tied to Cushing’s control and metabolic endpoints.
Named species claims align with this recordkeeping and can simplify proof.
How strong is the patent estate likely to be around this subject matter?
Answer: Based on the claim scope provided, the patent is narrow in one respect (it requires a specific dosing reduction to 600 mg from a specified baseline and a closed inhibitor list) but broad in another respect (multiple endpoints and multiple listed inhibitors).
Strength factors from the claim text
(These are analytical considerations derived from claim language structure, not from external procedural posture.)
What does this imply for generic entry and “at-risk” prescribing?
Answer: Even if a generic mifepristone is available, these claims do not protect the molecule per se. They protect a specific clinical regimen combining dose adjustment and strong CYP3A inhibitors in defined conditions.
Generic entry scenario impact
- Generic sponsors may face risk if they promote label language or patient management protocols that would induce clinicians to follow the patented regimen for patients previously on 900/1200 mg daily.
- The main exposure is less about manufacturing and more about post-marketing practice and potential regulatory or educational materials that could encourage the claimed combination.
“At-risk” prescribing levers
- Avoiding the specific dose adjustment (not reducing to 600 mg) and avoiding any inhibitor outside the enumerated list reduces risk.
- Prescribing patterns that do not include a prior 900/1200 mg mifepristone phase reduce direct match to the claims as written.
Where does US 10,195,214 sit relative to typical Orange Book-style exclusivity?
Answer: The patent is a U.S. method-of-use patent directed to dosing and drug-drug interaction management. In Orange Book terms, such patents are typically listed under the brand’s product listing as method-of-use protection for a specific indication or regimen.
Practical listing relevance
For freedom-to-operate analyses, the key question is whether this patent is:
- tied to a listed drug in the Orange Book,
- asserted as a method-of-use protection against Paragraph IV certifications (if any generics target the same listed drug),
- relevant to FDA labeling changes or interaction warnings that could influence prescribing.
(Determining the exact Orange Book status, listed claims, and any relevant Paragraph IV challenges requires Orange Book and litigation records, which are not provided in the prompt.)
Litigation and settlement risk: what claim scope supports?
Answer: The clear dose adjustment and closed inhibitor list create a litigation-friendly framework: accused regimens are identifiable by medication history and concomitant therapy, and dependent species claims help target specific co-medications.
What would be central in an infringement case
- Evidence a patient was on 900 mg or 1200 mg once daily before dose reduction.
- Proof the regimen reduced to 600 mg once daily.
- Proof the concomitant drug was one of the enumerated strong CYP3A inhibitors.
- Medical records connecting the method to the claimed endpoint (Cushing’s syndrome, elevated cortisol symptoms, or hyperglycemia control in endogenous Cushing’s).
Key Takeaways
- US 10,195,214 claims a method-of-treatment using a specific mifepristone dose adjustment to 600 mg once daily after patients were on 900 mg or 1200 mg once daily, combined with a strong CYP3A inhibitor selected from a closed enumerated list.
- Endpoint coverage spans Cushing’s syndrome, elevated cortisol symptom control, and hyperglycemia secondary to hypercortisolism in endogenous Cushing’s.
- Dependent claims add strong hooks for ketoconazole, itraconazole, and clarithromycin, aligning with common clinical co-prescribing patterns.
- For design-around and risk management, the critical avoidable elements are: not reducing to 600 mg, not using an enumerated inhibitor, and not having patients on the specified 900/1200 mg baseline prior to the reduction step.
FAQs
-
Does US 10,195,214 protect mifepristone itself or only the dosing regimen?
It is directed to a method of treatment involving a specific dose reduction to 600 mg and co-administration with enumerated strong CYP3A inhibitors.
-
What is the key dosing trigger in the independent claims?
The patient must be taking mifepristone at 1200 mg or 900 mg once daily before the reduction step to 600 mg once daily.
-
Which CYP3A inhibitors are explicitly named in the claims?
The claims list ketoconazole, itraconazole, nefazodone, ritonavir, nelfmavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranivir, paritaprevir, and voriconazole.
-
Can the claims be met with any CYP3A inhibitor, or only those listed?
The inhibitor is limited to those selected from the claim’s enumerated group.
-
Are different disease endpoints required for infringement under different claims?
Yes. The patent includes separate claim embodiments tied to treating Cushing’s syndrome, treating cortisol-related symptoms, or controlling hyperglycemia in endogenous Cushing’s.
References (APA)
- US Patent 10,195,214, “Method of treating Cushing’s syndrome using mifepristone with strong CYP3A inhibitors,” claims as provided in prompt.
More… ↓
⤷ Start Trial
|
